Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel.

Autor:	Shachor-Meyouhas Y; Paediatric Infectious Disease Unit, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel; Management, Rambam Health Care Campus, Haifa, Israel; The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: y_shahor@rambam.health.gov.il., Hussein K; The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Infection Control Unit, Rambam Health Care Campus, Haifa, Israel., Dabaja-Younis H; Paediatric Infectious Disease Unit, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel., Szwarcwort-Cohen M; Virology Laboratory, Rambam Health Care Campus, Haifa, Israel., Almog R; Epidemiology Department and Biobank, Rambam Health Care Campus, Haifa, Israel; School of Public Health, University of Haifa, Haifa, Israel., Weissman A; Management, Rambam Health Care Campus, Haifa, Israel., Mekel M; Management, Rambam Health Care Campus, Haifa, Israel; The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel., Hyams G; Nursing Management, Rambam Health Care Campus, Haifa, Israel., Horowitz NA; Management, Rambam Health Care Campus, Haifa, Israel; The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Gepstein V; Management, Rambam Health Care Campus, Haifa, Israel; Department of Paediatrics B, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel., Netzer I; Management, Rambam Health Care Campus, Haifa, Israel., Saban HC; Epidemiology Department and Biobank, Rambam Health Care Campus, Haifa, Israel., Petersiel N; Infectious Disease Unit, Rambam Health Care Campus, Haifa, Israel., Tarabeia J; Infection Control Unit, Rambam Health Care Campus, Haifa, Israel; Nursing Faculty, The Max Stern Yezreel Valley College, Yezreel Valley, Israel., Halberthal M; Management, Rambam Health Care Campus, Haifa, Israel; The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Jazyk:	angličtina
Zdroj:	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2022 Mar; Vol. 28 (3), pp. 450.e1-450.e4. Date of Electronic Publication: 2021 Nov 24.
DOI:	10.1016/j.cmi.2021.11.014
Abstrakt:	Objectives: We evaluated the antibody response to the BNT162B2 vaccine among healthcare workers (HCWs) to identify factors associated with decreased immunogenicity. Methods: This prospective cohort study included consenting HCWs who completed a questionnaire regarding background illnesses, medications, and post-vaccination allergic reactions or rash. All HCWs were tested for anti-spike antibodies (LIAISON SARS-CoV-2 S1/S2 IgG assay) 1 and 3 months after the second vaccine dose. A multivariate mixed linear model was adjusted to participants' data and fit to predict antibody levels after the second BNT162B2 vaccine dose, based on antibody levels at 1 month and the slope between 3 months and 1 month. Multivariate analyses identified factors associated with lower antibody levels. Results: In total 1506 HCWs were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. Older age was associated with lower mean antibody levels (-1.22 AU/mL, p < 0.001, 95%CI -1.43 to -1.01). In addition, male sex (-22.16 AU/mL, p < 0.001, 95%CI -27.93 to -16.39), underlying condition (-10.86 AU/mL, p 0.007, 95%CI -18.81 to -2.91) and immunosuppressive treatment (-28.57 AU/mL, p 0.002, 95%CI -46.85 to -10.29) were associated with significantly lower mean antibody levels. Allergic reactions after vaccine administration or peri-vaccination glucocorticosteroid treatment were not correlated with antibody levels. Conclusions: Most HCWs had measurable antibodies at 3 months. Risk factors for lower antibody levels were older age, male sex, underlying condition, and immunosuppressive treatment. These factors may be considered when planning booster doses during vaccine shortages. (Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu